Commercial J&J sets the tone for Q1 earnings with strong oncology growth Pharmaceutical TechnologyOff the back of J J's positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med IcotydeCommercialOncologyRead full story pharminent April 15, 2026 Pharmaceutical Technology Off the back of J J’s positive Q1, CEO Joaquin Duato forecasts strong growth acceleration for 2026, driven partially by psoriasis med Icotyde CommercialOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Amazon launches its AI drug discovery platformNext: Adcendo secures $75m in Series C funding for ADC development Related Stories Commercial Post-marketing oncology studies: Enabling faster recruitment and lower costs pharminent June 22, 2026 Commercial The first 14 days: How specialty programs set patients up for success pharminent June 22, 2026 Commercial Denali sells FDA voucher for $195M to support neurodegenerative pipeline pharminent June 19, 2026
